Novo Nordisk A/S: Non-alcoholic Fatty Liver Disease trials

The registry lists 18 Non-alcoholic Fatty Liver Disease studies with Novo Nordisk A/S as lead sponsor. 1 are open to participants now and 6 have results posted.

Phase 1 8Phase 2 7Phase 3 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASHRecruitingNCT06528314Phase 3
• A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)CompletedNCT05039450Phase 2Results posted
• A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)CompletedNCT04767529Phase 2Results posted
• A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic SteatohepatitisTerminatedNCT04004325Phase 1/2Results posted
• A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver DamageCompletedNCT03987451Phase 2Results posted
• A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)CompletedNCT03976401Phase 2Results posted
• Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.CompletedNCT02970942Phase 2Results posted
• A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver FatActive, not recruitingNCT07214870Phase 1
• A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children.CompletedNCT06188026Phase 1
• A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Active, not recruitingNCT06161571Phase 3
• A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate FormulationsCompletedNCT05766709Phase 1
• Barriers to MASLD Management in Europe: Findings From a Multidisciplinary HCP-surveyCompletedNCT05765890
• A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese MenCompletedNCT05742919Phase 1
• A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney FunctionCompletedNCT05727644Phase 1
• Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)CompletedNCT05016882Phase 2
• Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)Active, not recruitingNCT04822181Phase 3
• A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian MenCompletedNCT04722653Phase 1
• A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the LiverCompletedNCT03357380Phase 1